Fragment screening and druggability assessment for the CBP/p300 KIX domain through protein-observed 19F NMR spectroscopy.
about
Applications of (19)F-NMR in Fragment-Based Drug DiscoveryDirect and Propagated Effects of Small Molecules on Protein-Protein Interaction NetworksDual Screening of BPTF and Brd4 Using Protein-Observed Fluorine NMR Uncovers New Bromodomain Probe MoleculesA cell is more than the sum of its (dilute) parts: A brief history of quinary structure.Weak Intermolecular Hydrogen Bonds with Fluorine: Detection and Implications for Enzymatic/Chemical Reactions, Chemical Properties, and Ligand/Protein Fluorine NMR Screening.BET Bromodomain Inhibitors with One-Step Synthesis Discovered from Virtual Screen.Targeting transcription is no longer a quixotic questParamagnetic relaxation enhancement for protein-observed 19F NMR as an enabling approach for efficient fragment screening.Combined ligand-observe (19)F and protein-observe (15)N,(1)H-HSQC NMR suggests phenylalanine as the key Δ-somatostatin residue recognized by human protein disulfide isomerase.Protein 19F-labeling using transglutaminase for the NMR study of intermolecular interactions.Tuning Sulfur Oxidation States on Thioether-Bridged Peptide Macrocycles for Modulation of Protein Interactions.Perfluoro-tert-butyl Homoserine Is a Helix-Promoting, Highly Fluorinated, NMR-Sensitive Aliphatic Amino Acid: Detection of the Estrogen Receptor·Coactivator Protein-Protein Interaction by 19F NMR.Protein-observed (19)F-NMR for fragment screening, affinity quantification and druggability assessment.Observing enzyme ternary transition state analogue complexes by 19F NMR spectroscopy.Roles of structural plasticity in chaperone HdeA activity are revealed by 19F NMR.
P2860
Q26738755-EE77B6A4-8713-45A1-AE5E-E326070CF5F0Q26784027-A36A6E6A-AAB2-4C34-8AEE-F74C02933DC5Q28833420-9FABF1C7-00D5-4DE3-B5F2-ED86611A4CD8Q30396491-3046DC6C-D3DF-4A42-A7F4-3395E9595015Q31084554-5B834DFD-1A1D-4D50-9773-A3E0005D9F4FQ38702568-6AAFF80C-78C5-460C-843D-1BDAFF9C3313Q41552169-86271F7F-A3AB-4432-9B9C-EBCA41257BA1Q41668867-AEAD5C56-1302-4EE8-B38B-C984CC92A4E1Q43069071-BFCA1F50-C3B5-41A7-8E01-A9B4D2334803Q47866184-DA613B89-5B29-4839-849F-F3A8396022C4Q48252469-BE159CE3-60E1-41CF-9E38-0CC6BDECF637Q48273411-6CDD4C11-18B4-4347-B9D0-19C0A1CD3643Q51642295-B6C28BD6-35D4-469C-AA6C-BD9D0A976421Q52331609-F7355535-684D-4817-8D89-FC9CBAE17052Q55182108-9E098CED-4664-4F81-B938-F28114C00D24
P2860
Fragment screening and druggability assessment for the CBP/p300 KIX domain through protein-observed 19F NMR spectroscopy.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Fragment screening and druggab ...... observed 19F NMR spectroscopy.
@en
Fragment screening and druggab ...... observed 19F NMR spectroscopy.
@nl
type
label
Fragment screening and druggab ...... observed 19F NMR spectroscopy.
@en
Fragment screening and druggab ...... observed 19F NMR spectroscopy.
@nl
prefLabel
Fragment screening and druggab ...... observed 19F NMR spectroscopy.
@en
Fragment screening and druggab ...... observed 19F NMR spectroscopy.
@nl
P2093
P2860
P356
P1476
Fragment screening and druggab ...... observed 19F NMR spectroscopy.
@en
P2093
Clifford T Gee
Edward J Koleski
William C K Pomerantz
P2860
P304
P356
10.1002/ANIE.201411658
P407
P577
2015-02-04T00:00:00Z